GlassScriptPhysician profile
Matthew Weiss
NPI 1275023277
$7,226.41
in general payments reported to CMS, 2019-2025
20 companies · $936 in 2025
The $936 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $13.61 · 2023: $5,906 · 2024: $220 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Travel and Lodging: $1,906 · Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Travel and Lodging | $1,906.02 |
| Food and Beverage | $1,155.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eminent Spine, LLC | $5,906.02 | 2023 | Eminent Spine Si Screw System |
| Phathom Pharmaceuticals, INC. | $182.31 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $164.55 | 2021-2022 | |
| Abbvie INC. | $161.96 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.68 | 2024-2025 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $120.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.01 | 2025 | Xifaxan, Relistor |
| Ardelyx, INC. | $91.54 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $57.77 | 2024-2025 | |
| Lilly USA, LLC | $54.12 | 2024-2025 | Omvoh |
| Mirum Pharmaceuticals, INC. | $46.17 | 2025 | Livmarli |
| Janssen Biotech, INC. | $44.80 | 2024-2025 | Tremfya |
| Pfizer INC. | $29.60 | 2025 | |
| Novo Nordisk INC | $25.90 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $24.14 | 2024 | Iqirvo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $19.38 | 2025 | Pancreaze |
| Celltrion USA INC. | $19.09 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $17.07 | 2024 | Dificid |
| Exact Sciences Corporation | $16.14 | 2025 | Cologuard Collection Kit |
| Echosens North America, INC. | $13.51 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.